In advanced NSCLC patients with EGFR mutations (including sensitizing and non-sensitizing mutations) and positive PD-L1 expression (>1%), only 1 in 11 patients (9%) responded to pembrolizumab 73. Here, CD274 is linked to non-small cell lung carcinoma.